CUMULATIVE SAFETY ASSESSMENT OF THE TAKEDA TETRAVALENT DENGUE VACCINE CANDIDATE IN PARTICIPANTS 4 TO 60 YEARS OLD

被引：0
|
作者：
Patel, Sanjay S. [1 ]
Rauscher, Martina [1 ]
Peng, Hang [2 ]
机构：
[1] Takeda Pharmaceut, Zurich, Switzerland
[2] Takeda Pharmaceut Int Inc, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 2021年 / 105卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1290
引用
收藏
页码：413 / 413
页数：1
相关论文
共 50 条
  • [41] SINGLE ADMINISTRATION OF LIVE-ATTENUATED TETRAVALENT DENGUE VACCINE CANDIDATE, KD-382, INDUCED LONG-LASTING (>3.5 YEARS) NEUTRALIZING ANTIBODY AGAINST ALL FOUR SEROTYPES IN DENGUE NAIVE CYNOMOLGUS MONKEYS
    Shinmura, Yasuhiko
    Yoshimura, Masaya
    Kameyama, Kazuhisa
    Sonoda, Kengo
    Yoksan, Sutee
    Kimachi, Kazuhiko
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2019, 101 : 246 - 246
  • [42] Phase I study of the safety and immunogenicity of rDEN4Δ30-200,201 a live attenuated virus vaccine candidate for dengue serotype 4
    Durbin, Anna R.
    McArthur, Julie H.
    Marron, Jennifer
    Wanionek, Kimberli
    Thumar, Bhavin
    Blaney, Joseph E.
    Murphy, Brian R.
    Whitehead, Stephen S.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (05): : 100 - 100
  • [43] Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia A Phase IIIb, Randomized, Open-label Study
    Hassan, Jamiyah
    Toh, Teck-Hock
    Sivapunniam, Selva Kumar
    Hasim, Ruziaton
    Ghazali, Nor Faizah
    Sulaiman, Sofiah
    Koh, Mia Tuang
    Meyer, Stephanie
    Toh, Myew-Ling
    Zocchetti, Celine
    Vigne, Claire
    Mascarenas, Cesar
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (08) : 774 - 781
  • [44] Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial (vol 395, pg 1423, 2020)
    Biswal, S.
    Borja-Tabora, C.
    Vargas, Martinez L.
    LANCET, 2020, 395 (10230): : 1114 - 1114
  • [45] SINGLE ADMINISTRATION OF LIVE-ATTENUATED TETRAVALENT DENGUE VACCINE CANDIDATE, KD-382, INDUCED LONG-LASTING (>2 YEARS) NEUTRALIZING ANTIBODY AGAINST ALL FOUR SEROTYPES IN CYNOMOLGUS MONKEYS
    Shinmura, Yasuhiko
    Takagi, Shota
    Yoshimura, Masaya
    Kameyama, Kazuhisa
    Sonoda, Kengo
    Kino, Yoichiro
    Yoksan, Sutee
    Fujii, Takashi
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 246 - 246
  • [46] Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America A Randomized Placebo-controlled Trial
    Coronel, Diana
    Garcia-Rivera, Enid J.
    Rivera, Doris Maribel
    Arredondo-Garcia, Jose Luis
    Dietze, Reynaldo
    Perroud, Ana Paula
    Cortes, Margarita
    Bonaparte, Matthew
    Wang, Hao
    Pagnon, Anke
    Jantet-Blaudez, Frederique
    Penalosa, Luis Andrey Rojas
    Dayan, Gustavo
    Zambrano, Betzana
    DiazGranados, Carlos A.
    Noriega, Fernando
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (10) : 961 - 968
  • [47] Results from a polarized Analysis of Safety Data of an adjuvanted Herpes Zoster Subunit Vaccine Candidate consisting of more than 14,500 Study Participants from the Age of 50 Years
    Lopez-Fauqued, Marta
    Campora, Laura
    Delannois, Frederique
    El Idrissi, Mohamed
    Ledent, Edouard
    Diez-Domingo, Javier
    McElhaney, Janet
    McNeil, Shelly
    De Looze, Ferdinandus
    Yeo, Wilfried
    da Silva, Fernanda Tamares
    Hain, Johannes
    INTERNIST, 2018, 59 : S64 - S64
  • [48] Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
    Ngoc Huu Tran
    Chansinghakul, Danaya
    Chong, Chia Yin
    Low, Chian Yong
    Shek, Lynette P.
    Chan Quang Luong
    Fargo, Carina
    Wartel, T. Anh
    Sun, Sunny
    Skipetrova, Anna
    Bouckenooghe, Alain
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (10) : 2315 - 2327
  • [49] Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study
    Diaz, Clemente
    Koren, Michael
    Lin, Leyi
    Martinez, Luis J.
    Eckels, Kenneth H.
    Campos, Maribel
    Jarman, Richard G.
    De La Barrera, Rafael
    Lepine, Edith
    Febo, Irma
    Vaughn, David W.
    Wilson, Todd M.
    Paris, Robert M.
    Schmidt, Alexander C.
    Thomas, Stephen J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2020, 102 (05): : 951 - 954
  • [50] Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
    Park, Juliana
    Archuleta, Sophia
    Oh, May-Lin Helen
    Shek, Lynette Pei-Chi
    Wang, Hao
    Bonaparte, Matthew
    Frago, Carina
    Bouckenooghe, Alain
    Jantet-Blaudez, Frederique
    Begue, Sarah
    Gimenez-Fourage, Sophie
    Pagnon, Anke
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (07) : 2107 - 2116
12345